New York, May 28, 2026, 17:02 EDT
- Polyrizon last traded at $16.50. Shares were flat. Volume was higher than usual.
- Ami Oren joined as a Class I director, effective May 14, according to an SEC filing posted May 27.
- Clinical progress on NASARIX, the company’s experimental allergy-blocking nasal spray, is still the next thing that could move the stock.
Polyrizon Ltd. (PLRZ) ended Thursday mostly flat as the Israel-based biotech named a new board member. The update didn’t include trial results or financing. Shares last traded at $16.50, up a penny. During the session, the price moved between $17.165 and $16.17.
Polyrizon is a micro-cap, with shares changing hands near the stock’s 52-week high. The company has a market value around $29.5 million, according to Robinhood, with volume at 76,000 shares, higher than the 35,650 average. Its 52-week range is $2.88 to $18.20.
Polyrizon named Ami Oren as a Class I director, the company said in a Form 6-K filed with U.S. regulators. The appointment took effect May 14. Oren, 51, has spent over two decades starting and running consumer businesses, according to the filing. He was founder and manager of Hummus Ami in Yavne, Israel, running it from 2015 until it was sold in 2026.
Polyrizon is looking to get NASARIX, or PL-14, ready for trials in humans. The company said on May 13 it signed a first U.S. clinical trial deal with an allergy research center in Texas for a planned multi-center study in people with seasonal allergic rhinitis.
Polyrizon CEO Tomer Izraeli called the agreement “an important step” as the company shifts NASARIX from development to possible clinical validation, according to the release. Izraeli also said Polyrizon is working with an “experienced clinical team” to move toward its first-in-human trial. GlobeNewswire
NASARIX is an investigational intranasal product. It’s delivered through the nose and aims to make a physical, non-drug barrier to airborne allergens. Polyrizon says the underlying tech uses medical device hydrogels—gels that coat the nasal cavity with a shield to block allergens or viruses from reaching nasal tissue.
Polyrizon pointed to Alzair Allergy Blocker, Nasalease Allergy Blocker and Bentrio Allergy Blocker as possible predicate devices for PL-14 in its IPO prospectus. A predicate device is an existing medical device already cleared, which companies use for comparison to seek U.S. clearance via the FDA’s 510(k) process. That approach allows companies to show substantial equivalence instead of new data from the ground up.
Polyrizon is expanding its patent portfolio tied to intranasal delivery. The company this month announced amended U.S. patent claims that aim to give it broader coverage for its platform, including systems and uses for drug delivery. Izraeli called the move “another important step” for the company’s IP. BioSpace
Board seats don’t always change the outlook for a pre-revenue biotech. Polyrizon, in its 2025 annual report, said it has yet to book any revenue, logged a $3.3 million net loss in 2025, burned $4.5 million in operating cash, and sees more losses ahead.
Regulatory timing remains an open question. The company says it needs to secure required clearances and approvals on schedule, or its growth plans could take a hit. Clinical trials also have to prove the product is both safe and effective — it has to deliver and avoid serious harm — before any real commercialization.
Nasdaq closed its regular session before this report came out. The main U.S. stock market hours at the exchange are 9:30 a.m. to 4:00 p.m. Eastern Time, and after-hours trading goes from 4:00 p.m. to 8:00 p.m.
